JY-2

CAS No. 339103-05-8

JY-2( —— )

Catalog No. M36546 CAS No. 339103-05-8

JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 45 Get Quote
10MG 76 Get Quote
25MG 150 Get Quote
50MG 227 Get Quote
100MG 335 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JY-2
  • Note
    Research use only, not for human use.
  • Brief Description
    JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.
  • Description
    JY-2 is a moderately selective and orally active Forkhead transcription factor forkhead box O1 (FoxO1) inhibitor that inhibits FoxO1 transcriptional activity with an IC50 of 22 μM. JY-2 shows moderate inhibition against FoxO3a and FoxO4. JY-2 shows anti-diabetic activity.
  • In Vitro
    Real Time qPCRCell Line:HepG2 and INS-1 cells Concentration:10, 50 and 100 μM Incubation Time:24 h Result:Reduced palmitic acid (PA)-induced G6Pase and PEPCK mRNA expression. Inhibited PA-induced lipid accumulation. Reduced PA-induced mRNA expression of ER stress markers (ATF3, CHOP and GRP78).Western Blot Analysis Cell Line:HepG2 cells Concentration:10, 50 and 100 μM Incubation Time:4 h; in the presence of PA (500μM)Result:Increased p-FoxO1 levels in the whole cell lysate with a concurrent reduction in nuclear FoxO1 levels.
  • In Vivo
    Animal Model:C57BL/6J mice Dosage:50, 100, 200 mg/kg Administration:Oral, three times for two days (9:00 AM, 7:00 PM, 9:00 AM on the next day)Result:Improved glucose tolerance. Significantly reduced the expression of G6Pase and PEPCK mRNA in the liver. Enhanced mRNA expression of insulin and PDX-1 in the pancreas.Animal Model:db/db mice and C57BL/6J mice, high fat-diet-induced obese diabetic (DIO) model Dosage:50, 100 mg/kg Administration:Oral, once daily for 4 weeks Result:Decreased the levels of fasting blood glucose, improved glucose tolerance. The expression of ColIV, a fibrosis marker, was also lowered.Animal Model:C57BL/6J mice Dosage:20 mg/kg or 50 mg/kg Administration:IV or PO (Pharmacokinetic Analysis) Result:Showed an overall good pharmacokinetic profile.
  • Synonyms
    ——
  • Pathway
    Nuclear Receptor/Transcription Factor
  • Target
    Foxo1
  • Recptor
    FOXO1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    339103-05-8
  • Formula Weight
    292.12
  • Molecular Formula
    C13H7Cl2N3O
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (427.91 mM; Ultrasonic (<60°C)
  • SMILES
    ClC1=CC(Cl)=C(C=C1)C1=NC(=NO1)C1=NC=CC=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Choi HE, et al. Novel FoxO1 inhibitor, JY-2, ameliorates palmitic acid-induced lipotoxicity and gluconeogenesis in a murine model. Eur J Pharmacol. 2021 May 15;899:174011.?
molnova catalog
related products
  • AS-1842856

    A novel transcription factor Foxo1 inhibitor that potently and selectively inhibits Foxo1-mediated transactivation with IC50 of 33 nM.

  • JY-2

    JY-2 is an orally active and selective forkhead transcription factor O1 (FoxO1) inhibitor with antidiabetic activity and inhibits FoxO1 transcription.JY-2 can be used to study psoriasis and diabetes.

  • FOXO1-IN-8

    A small molecule, selective FOXO1 inhibitor that inhibits FOXO-dependent glucose production devoid of lipogenic activity in hepatocytes.